Trastuzumab deruxtecan in HER2-positive metastatic breast cancer with severe hepatic dysfunction: a case report and narrative literature review
Trastuzumab deruxtecan (T-DXd) has transformed the management of Human Epidermal Growth Factor Receptor 2 (HER2)-positive metastatic breast cancer (mBC). However, its role in visceral crisis (VC) remains unclear due to exclusion from clinical trials and limited real-world evidence. We report the case of a 40-year-old w...